- Home
- Publications
- Publication Search
- Publication Details
Title
The landscape of bispecific T cell engager in cancer treatment
Authors
Keywords
-
Journal
Biomarker Research
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-26
DOI
10.1186/s40364-021-00294-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial
- (2020) Sabina Chiaretti et al. BLOOD
- Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- (2020) Marion Subklewe et al. BLOOD
- Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
- (2020) Peter Westervelt et al. BLOOD
- First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
- (2020) Luciano J. Costa et al. BLOOD
- Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia
- (2020) Hitoshi Kiyoi et al. CANCER SCIENCE
- Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Horst-Dieter Hummel et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- CAR T cells: continuation in a revolution of immunotherapy
- (2020) Anurag K Singh et al. LANCET ONCOLOGY
- Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors
- (2020) Caroline E. Porter et al. MOLECULAR THERAPY
- DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
- (2020) Patrick J. Engelberts et al. EBioMedicine
- Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma
- (2020) Cristina Perez et al. BLOOD
- First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).
- (2020) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.
- (2020) Joseph Chao et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
- (2020) Hanren Dai et al. Journal of Hematology & Oncology
- Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
- (2020) Keisuke Yamamoto et al. NATURE
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- T cell-engaging therapies — BiTEs and beyond
- (2020) Maria-Elisabeth Goebeler et al. Nature Reviews Clinical Oncology
- Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
- (2020) Luke Coyle et al. LEUKEMIA & LYMPHOMA
- Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia
- (2020) Nicola Gökbuget et al. LEUKEMIA & LYMPHOMA
- Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
- (2020) Franco Locatelli et al. Blood Cancer Journal
- Hyper-CVAD: a regimen for all seasons
- (2020) Matthew D Seftel Lancet Haematology
- Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
- (2020) Zong Sheng Guo et al. Biomedicines
- 609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
- (2020) B. Tran et al. ANNALS OF ONCOLOGY
- Tumor intrinsic and extrinsic determinants of response to blinatumomab in adults with B-ALL
- (2020) Yaqi Zhao et al. BLOOD
- Mechanistic Prediction of First-in-Human Dose for Bispecific CD3/EpCAM T-cell engager Antibody M701, using an Integrated PK/PD Modeling Method
- (2020) Ling Song et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
- (2020) Andras Heczey et al. NATURE MEDICINE
- Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
- (2020) Zhen Zhang et al. Journal for ImmunoTherapy of Cancer
- Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
- (2020) Kodandaram Pillarisetti et al. Blood Advances
- Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
- (2019) Delong Liu et al. Journal of Hematology & Oncology
- A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
- (2019) Frans V. Suurs et al. PHARMACOLOGY & THERAPEUTICS
- Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies
- (2019) Ping-Pin Zheng et al. TRENDS IN IMMUNOLOGY
- Rapid Relapse of Large B‐Cell Lymphoma after CD19 Directed CAR‐T‐Cell Therapy due to CD‐19 Antigen Loss
- (2019) Ali Bukhari et al. AMERICAN JOURNAL OF HEMATOLOGY
- Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
- (2019) Laurent Gauthier et al. CELL
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
- (2019) Bryan D. Choi et al. NATURE BIOTECHNOLOGY
- Mechanisms of immunotherapy resistance: lessons from glioblastoma
- (2019) Christopher M. Jackson et al. NATURE IMMUNOLOGY
- Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
- (2019) Michael Friedrich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Functional diversification of IgGs through Fc glycosylation
- (2019) Taia T. Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
- (2019) Shengnan Yu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
- (2019) Zsolt Sebestyen et al. NATURE REVIEWS DRUG DISCOVERY
- TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion
- (2019) Harbani Malik et al. BLOOD
- Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma
- (2019) Deborah A. Katz et al. BLOOD
- Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
- (2019) Krish Patel et al. BLOOD
- Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
- (2019) Amber C. King et al. BLOOD
- Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia
- (2019) Shaun Fleming et al. BLOOD
- Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Noopur S. Raje et al. BLOOD
- Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- (2019) Guillaume Richard-Carpentier et al. BLOOD
- Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias
- (2019) James K McCloskey et al. BLOOD
- Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse
- (2019) Koji Sasaki et al. BLOOD
- Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504
- (2019) Marc Schwartz et al. BLOOD
- Blinatumomab and Venetoclax for Minimal Residual Disease Relapse in Acute Lymphoblastic Leukemia
- (2019) Gregorio Campos-Cabrera et al. BLOOD
- Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events
- (2019) Matthias Klinger et al. CANCER RESEARCH
- MHC-II neoantigens shape tumour immunity and response to immunotherapy
- (2019) Elise Alspach et al. NATURE
- ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)
- (2019) Mark A Rosenthal et al. NEURO-ONCOLOGY
- Silencing Fc Domains in T cell–Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency
- (2019) Linlin Wang et al. Cancer Immunology Research
- Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples
- (2019) Eleanor M. Scott et al. Journal for ImmunoTherapy of Cancer
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
- (2018) Nicola Gökbuget et al. BLOOD
- Bispecific antibody based therapeutics: Strengths and challenges
- (2018) Archana Thakur et al. BLOOD REVIEWS
- Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
- (2018) Colin E. Correnti et al. LEUKEMIA
- Development of MGD007, a gpA33 x CD3 bispecific DART® protein for T-cell immunotherapy of metastatic colorectal cancer
- (2018) Paul A Moore et al. MOLECULAR CANCER THERAPEUTICS
- Myeloid-derived suppressor cells coming of age
- (2018) Filippo Veglia et al. NATURE IMMUNOLOGY
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia
- (2018) Matthew J. Oberley et al. PEDIATRIC BLOOD & CANCER
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors
- (2018) Anthony S. Stein et al. ANNALS OF HEMATOLOGY
- An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells
- (2018) Joshua D. Freedman et al. CANCER RESEARCH
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
- (2018) Christopher S. Garris et al. IMMUNITY
- Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
- (2017) Nicola Gökbuget et al. HAEMATOLOGICA
- Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
- (2017) Giovanni Martinelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
- (2017) J Duell et al. LEUKEMIA
- Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
- (2017) Alec J. Walker et al. MOLECULAR THERAPY
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
- (2017) Takahiro Ishiguro et al. Science Translational Medicine
- Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
- (2017) Nicola Gökbuget et al. HAEMATOLOGICA
- Myeloid-Derived Suppressor Cells
- (2017) Dmitry I. Gabrilovich Cancer Immunology Research
- A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells
- (2017) Renée C. G. de Bruin et al. OncoImmunology
- Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma
- (2016) Hui Yu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2016) D. Hoelzer et al. ANNALS OF ONCOLOGY
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
- (2016) A. Viardot et al. BLOOD
- Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
- (2016) Friederike Braig et al. BLOOD
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
- (2016) R. Gardner et al. BLOOD
- MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
- (2016) Liqin Liu et al. CLINICAL CANCER RESEARCH
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions
- (2016) Matthias Klinger et al. IMMUNOLOGICAL REVIEWS
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
- (2016) Marco Ruella et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
- (2016) Arend von Stackelberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- (2016) G. Hernandez-Hoyos et al. MOLECULAR CANCER THERAPEUTICS
- Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker
- (2016) Joerg U Schmohl et al. MOLECULAR THERAPY
- Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy
- (2016) Ahmad Rayes et al. PEDIATRIC BLOOD & CANCER
- Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
- (2016) Tilman Schlothauer et al. PROTEIN ENGINEERING DESIGN & SELECTION
- T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
- (2016) Judith Feucht et al. Oncotarget
- Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia
- (2016) N. V. Frey et al. Hematology-American Society of Hematology Education Program
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
- (2015) Thomas Köhnke et al. Journal of Hematology & Oncology
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells
- (2015) Uwe Reusch et al. mAbs
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
- (2015) G S Laszlo et al. Blood Cancer Journal
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+T Cells
- (2014) Keisuke Watanabe et al. JOURNAL OF IMMUNOLOGY
- Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
- (2014) H. Xu et al. Cancer Immunology Research
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered
- (2013) Hui K. Gan et al. FEBS Journal
- Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system
- (2013) C Arndt et al. LEUKEMIA
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- Piecing together the family portrait of TCR-CD3 complexes
- (2012) Michael S. Kuhns et al. IMMUNOLOGICAL REVIEWS
- Expression of tumour-specific antigens underlies cancer immunoediting
- (2012) Michel DuPage et al. NATURE
- Blinatumomab: A historical perspective
- (2012) Dirk Nagorsen et al. PHARMACOLOGY & THERAPEUTICS
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficient Inhibition of Human B-cell Lymphoma in SCID Mice by Synergistic Antitumor Effect of Human 4-1BB Ligand/Anti-CD20 Fusion Proteins and Anti-CD3/Anti-CD20 Diabodies
- (2010) Rong Liu et al. JOURNAL OF IMMUNOTHERAPY
- T Cell Activation
- (2009) Jennifer E. Smith-Garvin et al. Annual Review of Immunology
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now